{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:39:31Z","timestamp":1792291171303,"version":"4.4.0"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>This scoping review prepared by endocrinology and nephrology experts aimed to address the significance of finerenone, as a novel therapeutic option, in diabetic kidney disease (DKD), based on the biological prospect of cardiorenal benefit due to non-steroidal mineralocorticoid receptor antagonist (MRA) properties, and the recent evidence from the finerenone phase 3 program clinical trials. The importance of finerenone in slowing DKD progression was critically reviewed in relation to the role of MR overactivation in the pathogenesis of cardiorenal disease and unmet needs in the current practice patterns. The efficacy and safety outcomes of finerenone phase III study program including FIDELIO-DKD, FIGARO-DKD and FIDELITY were presented. Specifically, perspectives on inclusion of patients with preserved estimated glomerular filtration rate (eGFR) or high albuminuria, concomitant use of sodium-glucose co-transporter-2 inhibitor (SGLT2i) or glucagon-like peptide 1 receptor agonist (GLP-1 RA), baseline glycated hemoglobin (HbA1c) level and insulin treatment, clinically meaningful heart failure outcomes and treatment-induced hyperkalemia were addressed. Finerenone has emerged as a new therapeutic agent that slows DKD progression, reduces albuminuria and risk of cardiovascular complications, regardless of the baseline HbA1c levels and concomitant treatments (SGLT2i, GLP-1 RA, or insulin) and with a favorable benefit-risk profile. The evolving data on the benefit of SGLT2is and non-steroidal MRAs in slowing or reducing cardiorenal risk seem to provide the opportunity to use these pillars of therapy in the management of DKD, after a long-period of treatment scarcity in this field. Along with recognition of the albuminuria as a powerful marker to detect those patients at high risk of cardiorenal disease, these important developments would likely to impact standard-of-care options in the setting of DKD.<\/jats:p>","DOI":"10.3389\/fmed.2024.1384454","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T04:53:54Z","timestamp":1718340834000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials"],"prefix":"10.3389","volume":"11","author":[{"given":"Mustafa","family":"Arici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Altun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Araz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysegul","family":"Atmaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tevfik","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tevfik","family":"Ecder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galip","family":"Guz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Gogas Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaattin","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temel","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ecl.2017.10.006","article-title":"Managing diabetes and cardiovascular risk in chronic kidney disease patients.","volume":"47","author":"Lovre","year":"2018","journal-title":"Endocrinol Metab Clin North Am."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.37765\/ajmc.2021.88660","article-title":"Targeted literature review of the burden of illness in patients with chronic kidney disease and type 2 diabetes.","volume":"27","author":"Fried","year":"2021","journal-title":"Am J Manag Care."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options.","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation."},{"key":"B5","year":"2021","journal-title":"IDF Diabetes Atlas."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/ndt\/gfaa294","article-title":"Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.","volume":"37","author":"Agarwal","year":"2022","journal-title":"Nephrol Dial Transplant."},{"key":"B7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.17925\/EE.2021.17.2.84","article-title":"Finerenone: a potential treatment for patients with chronic kidney disease and type 2 diabetes mellitus.","volume":"17","author":"D\u2019Marco","year":"2021","journal-title":"touchREV Endocrinol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/dom.14696","article-title":"Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.","volume":"24","author":"DeFronzo","year":"2022","journal-title":"Diabetes Obes Metab."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01676-5","article-title":"Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.","volume":"21","author":"Zhang","year":"2022","journal-title":"Cardiovasc Diabetol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.13969","article-title":"Pathophysiologic mechanisms in diabetic kidney disease: a focus on current and future therapeutic targets.","volume":"22","author":"Barrera-Chimal","year":"2020","journal-title":"Diabetes Obes Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","article-title":"2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. a consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD).","volume":"63","author":"Buse","year":"2020","journal-title":"Diabetologia."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1042\/CS20220212","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease.","volume":"136","author":"Barrera-Chimal","year":"2022","journal-title":"Clin Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","article-title":"Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases.","volume":"84","author":"Barrera-Chimal","year":"2022","journal-title":"Annu Rev Physiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat Rev Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development.","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling.","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial.","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes.","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1053\/j.ajkd.2021.02.324","article-title":"Finerenone\u2014a new frontier in renin-angiotensin-aldosterone system inhibition in diabetic kidney disease.","volume":"78","author":"Sridhar","year":"2021","journal-title":"Am J Kidney Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.2337\/dc23-S011","article-title":"on behalf of the American diabetes association. 11. chronic kidney disease and risk management: standards of care in diabetes-2023.","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care."},{"key":"B25","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update.","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract."},{"key":"B26","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease.","volume":"102","year":"2022","journal-title":"Kidney Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2337\/diacare.27.1.195","article-title":"Nonalbuminuric renal insufficiency in type 2 diabetes.","volume":"27","author":"MacIsaac","year":"2004","journal-title":"Diabetes Care."},{"key":"B28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.ajkd.2011.02.391","article-title":"High-normal albuminuria and risk of heart failure in the community.","volume":"58","author":"Blecker","year":"2011","journal-title":"Am J Kidney Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1681\/ASN.2006101159","article-title":"Reduced kidney function as a risk factor for incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study.","volume":"18","author":"Kottgen","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration with the US food and drug administration and European medicines agency.","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1681\/ASN.2020050723","article-title":"Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE trial.","volume":"31","author":"Oshima","year":"2020","journal-title":"J Am Soc Nephrol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1053\/j.ajkd.2013.01.005","article-title":"The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the kidney early evaluation program (KEEP).","volume":"61","author":"Amin","year":"2013","journal-title":"Am J Kidney Dis."},{"key":"B34","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"3","year":"2013","journal-title":"Kidney Int Suppl."},{"key":"B35","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update.","volume":"60","year":"2012","journal-title":"Am J Kidney Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities.","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10741-014-9460-9","article-title":"Chronic kidney disease and cardiovascular complications.","volume":"20","author":"Di Lullo","year":"2015","journal-title":"Heart Fail Rev."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-0942-1","article-title":"Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus.","volume":"19","author":"Go","year":"2018","journal-title":"BMC Nephrol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/sj.ki.5000058","article-title":"The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age.","volume":"69","author":"Eriksen","year":"2006","journal-title":"Kidney Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1681\/ASN.2014070714","article-title":"Cause of death in patients with reduced kidney function.","volume":"26","author":"Thompson","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.ekir.2021.05.027","article-title":"Mineralocorticoid receptor antagonism in chronic kidney disease.","volume":"6","author":"Georgianos","year":"2021","journal-title":"Kidney Int Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes.","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside.","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/hypertensionaha.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension."},{"key":"B45","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejim.2013.11.007","article-title":"Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy:a systematic review.","volume":"25","author":"Mavrakanas","year":"2014","journal-title":"Eur J Intern Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3803\/EnM.2021.987","article-title":"Cardiorenal protection in diabetic kidney disease.","volume":"36","author":"Lee","year":"2021","journal-title":"Endocrinol Metab."},{"key":"B47","first-page":"25","article-title":"The importance of early identification of chronic kidney disease.","volume":"108","author":"Whaley-Connell","year":"2011","journal-title":"Mo Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/IJNRD.S37893","article-title":"Inhibition of RAS in diabetic nephropathy.","volume":"8","author":"Yacoub","year":"2015","journal-title":"Int J Nephrol Renovasc Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"on behalf of the American diabetes association. 9. pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023.","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1111\/j.1523-1755.2004.00925.x","article-title":"Progression of nephropathy in type 2 diabetic patients.","volume":"66","author":"Rossing","year":"2004","journal-title":"Kidney Int."},{"key":"B51","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) group.","volume":"352","year":"1998","journal-title":"Lancet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/ki.2012.401","article-title":"Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.","volume":"83","author":"Perkovic","year":"2013","journal-title":"Kidney Int."},{"key":"B53","doi-asserted-by":"publisher","first-page":"694","DOI":"10.2337\/dc15-2322","article-title":"Long-term benefits of intensive glucose control for preventing end-stage kidney disease: advanceon.","volume":"39","author":"Wong","year":"2016","journal-title":"Diabetes Care."},{"key":"B54","doi-asserted-by":"publisher","first-page":"888","DOI":"10.2337\/dc21-1944","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes according to baseline HbA1c and insulin use: an analysis from the FIDELIO-DKD study.","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care."},{"key":"B55","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat Rev Nephrol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomized trials.","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.nefro.2020.10.001","article-title":"Mineralcorticoid receptor blockers in chronic kidney disease.","volume":"41","author":"Erraez","year":"2021","journal-title":"Nefrologia."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy.","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes.","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American heart association.","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension.","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry.","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail."},{"key":"B67","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care."},{"key":"B68","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.kint.2017.08.038","article-title":"Revisiting RAAS blockade in CKD with newer potassium-binding drugs.","volume":"93","author":"Georgianos","year":"2018","journal-title":"Kidney Int."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br J Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1.","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem."},{"key":"B71","doi-asserted-by":"publisher","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem."},{"key":"B72","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity.","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension."},{"key":"B73","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist Finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress.","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension."},{"key":"B74","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jash.2016.05.013","article-title":"Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials.","volume":"10","author":"Zhao","year":"2016","journal-title":"J Am Soc Hypertens."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease.","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J."},{"key":"B77","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000528783","article-title":"Mineralocorticoid receptor-associated mechanisms in diabetic kidney disease and clinical significance of mineralocorticoid receptor antagonists.","volume":"54","author":"Mende","year":"2023","journal-title":"Am J Nephrol."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.754239","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease.","volume":"12","author":"Kawanami","year":"2021","journal-title":"Front Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes.","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation."},{"key":"B80","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial.","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes Metab."},{"key":"B81","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"key":"B82","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy.","volume":"7","author":"Rossing","year":"2021","journal-title":"Kidney Int Rep."},{"key":"B83","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant."},{"key":"B84","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13340-020-00444-8","article-title":"Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches.","volume":"11","author":"Kitada","year":"2020","journal-title":"Diabetol Int."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.006260","article-title":"Type 2 diabetes mellitus and impact of heart failure on prognosis compared to other cardiovascular diseases: a nationwide study.","volume":"13","author":"Zareini","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"B86","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial.","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100739","article-title":"Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years.","volume":"32","author":"Lawson","year":"2021","journal-title":"EClinicalMedicine."},{"key":"B88","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with Finerenone: results from the FIDELIO-DKD Trial.","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference.","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int."},{"key":"B90","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease.","volume":"34","author":"Lazich","year":"2014","journal-title":"Semin Nephrol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/eurheartj\/ehy100","article-title":"Serum potassium and adverse outcomes across the range of kidney function: a CKD prognosis consortium meta-analysis.","volume":"39","author":"Kovesdy","year":"2018","journal-title":"Eur Heart J."},{"key":"B92","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000492622","article-title":"Patiromer to enable spironolactone use in the treatment of patients with resistant hypertension and chronic kidney disease: rationale and design of the AMBER study.","volume":"48","author":"Agarwal","year":"2018","journal-title":"Am J Nephrol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ejhf.218","article-title":"Rationale and design of mineralocorticoid receptor antagonist tolerability study-heart failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease.","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail."},{"key":"B94","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cpdd.263","article-title":"Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment.","volume":"5","author":"Heinig","year":"2016","journal-title":"Clin Pharmacol Drug Dev."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012655","article-title":"Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom.","volume":"8","author":"Linde","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B96","first-page":"283","article-title":"Hyperkalemia.","volume":"73","author":"Hollander-Rodriguez","year":"2006","journal-title":"Am Fam Physician."},{"key":"B97","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrneph.2014.168","article-title":"Management of hyperkalaemia in chronic kidney disease.","volume":"10","author":"Kovesdy","year":"2014","journal-title":"Nat Rev Nephrol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000521908","article-title":"Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease.","volume":"47","author":"Zheng","year":"2022","journal-title":"Kidney Blood Press Res."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41746","article-title":"Systematic review and meta-analysis on the efficacy and safety of finerenone therapy in patients with cardiovascular and chronic kidney diseases in type 2 diabetes mellitus.","volume":"15","author":"Jyotsna","year":"2023","journal-title":"Cureus."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00228-022-03408-w","article-title":"Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials.","volume":"78","author":"Bao","year":"2022","journal-title":"Eur J Clin Pharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1097\/MS9.0000000000001180","article-title":"Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis.","volume":"85","author":"Yasmin","year":"2023","journal-title":"Ann Med Surg."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.896947","article-title":"Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes: a systematic review incorporating an indirect comparisons meta-analysis.","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Pharmacol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5582\/irdr.2020.01008","article-title":"The cardiovascular outcomes of finerenone in patients with chronic kidney disease and type 2 diabetes: a meta-analysis of randomized clinical trials.","volume":"11","author":"Abdelazeem","year":"2022","journal-title":"Intractable Rare Dis Res."},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1114894","article-title":"Finerenone in type 2 diabetes and renal outcomes: a random-effects model meta-analysis.","volume":"14","author":"Ghosal","year":"2023","journal-title":"Front Endocrinol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/FJC.0000000000001364","article-title":"Efficacy and safety of finerenone for prevention of cardiovascular events in type 2 diabetes mellitus with chronic kidney disease: a meta-analysis of randomized controlled trials.","volume":"81","author":"Yang","year":"2023","journal-title":"J Cardiovasc Pharmacol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s11255-022-03432-w","article-title":"Effect of finerenone on cardiovascular events in kidney disease and\/or diabetes: a meta analysis of randomized control trials.","volume":"55","author":"Zhu","year":"2023","journal-title":"Int Urol Nephrol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4103\/ijem.ijem_376_21","article-title":"Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: a meta-analysis.","volume":"26","author":"Dutta","year":"2022","journal-title":"Indian J Endocrinol Metab."},{"key":"B109","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13098-023-01251-2","article-title":"Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis.","volume":"16","author":"Gu","year":"2024","journal-title":"Diabetol Metab Syndr."},{"key":"B110","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13098-022-00929-3","article-title":"Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease.","volume":"14","author":"Zhang","year":"2022","journal-title":"Diabetol Metab Syndr."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.751496","article-title":"Network meta-analysis on the effects of SGLT2 inhibitors versus finerenone on cardiorenal outcomes in patients with type 2 diabetes and chronic kidney disease.","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Pharmacol."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074068","article-title":"Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.","volume":"381","author":"Shi","year":"2023","journal-title":"BMJ."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1384454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T04:54:02Z","timestamp":1718340842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1384454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":112,"alternative-id":["10.3389\/fmed.2024.1384454"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1384454","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]},"article-number":"1384454"}}